Geographic Segments

9 Months Ended

Mar. 31, 2016

Geographic Segments [Abstract]

Geographic Segments

8.Geographic Segments

Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment. Immunomedics conducts its research and development activities primarily in the United States. Immunomedics markets and sells LeukoScan® throughout Europe and in certain other countries outside the United States.

The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the three and nine-months ended March 31, 2016 and 2015, respectively ($ in thousands):

	As of and for the three months ended
	March 31, 2016
		United
		States		Europe		Total
Total assets	$	66,324	$	1,318	$	67,642
Property and equipment, net		3,099		69		3,168
Revenues		356		543		899
Loss before taxes		(15,789)		(104)		(15,893)

	As of and for the three months ended
	March 31, 2015
		United
		States		Europe		Total
Total assets	$	110,600	$	1,234	$	111,834
Property and equipment, net		2,056		9		2,065
Revenues		489		694		1,183
Loss before taxes		(11,762)		(23)		(11,785)

	Nine Months Ended
	March 31, 2016
		United
		States		Europe		Total
Revenues	$	587	$	1,714	$	2,301
Loss before taxes		(47,977)		(290)		(48,267)

	Nine Months Ended
	March 31, 2015
		United
		States		Europe		Total
Revenues	$	1,110	$	2,147	$	3,257
Loss before taxes		(35,733)		79		(35,654)